These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
865 related articles for article (PubMed ID: 29051064)
1. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment. Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064 [TBL] [Abstract][Full Text] [Related]
2. Dendritic cell-mediated delivery of doxorubicin-polyglycerol-nanodiamond composites elicits enhanced anti-cancer immune response in glioblastoma. Li TF; Li K; Zhang Q; Wang C; Yue Y; Chen Z; Yuan SJ; Liu X; Wen Y; Han M; Komatsu N; Xu YH; Zhao L; Chen X Biomaterials; 2018 Oct; 181():35-52. PubMed ID: 30071380 [TBL] [Abstract][Full Text] [Related]
3. Doxorubicin-polyglycerol-nanodiamond composites stimulate glioblastoma cell immunogenicity through activation of autophagy. Li TF; Xu YH; Li K; Wang C; Liu X; Yue Y; Chen Z; Yuan SJ; Wen Y; Zhang Q; Han M; Komatsu N; Zhao L; Chen X Acta Biomater; 2019 Mar; 86():381-394. PubMed ID: 30654213 [TBL] [Abstract][Full Text] [Related]
4. Monocyte-mediated chemotherapy drug delivery in glioblastoma. Wang C; Li K; Li T; Chen Z; Wen Y; Liu X; Jia X; Zhang Y; Xu Y; Han M; Komatsu N; Zhao L; Chen X Nanomedicine (Lond); 2018 Jan; 13(2):157-178. PubMed ID: 29173008 [TBL] [Abstract][Full Text] [Related]
5. Doxorubicin conjugated with nanodiamonds and in free form commit glioblastoma cells to heterodromous fates. Chen Z; Wang C; Li TF; Li K; Yue Y; Liu X; Xu HZ; Wen Y; Zhang Q; Han M; Komatsu N; Xu YH; Zhao L; Chen X Nanomedicine (Lond); 2019 Feb; 14(3):335-351. PubMed ID: 30676239 [TBL] [Abstract][Full Text] [Related]
6. Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells. Xu HZ; Li TF; Wang C; Ma Y; Liu Y; Zheng MY; Liu ZJ; Chen JB; Li K; Sun SK; Komatsu N; Xu YH; Zhao L; Chen X J Nanobiotechnology; 2021 Sep; 19(1):268. PubMed ID: 34488792 [TBL] [Abstract][Full Text] [Related]
7. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer. Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629 [TBL] [Abstract][Full Text] [Related]
8. Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme. Yang FY; Wong TT; Teng MC; Liu RS; Lu M; Liang HF; Wei MC J Control Release; 2012 Jun; 160(3):652-8. PubMed ID: 22405901 [TBL] [Abstract][Full Text] [Related]
9. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity. Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502 [TBL] [Abstract][Full Text] [Related]
10. Sustained Delivery of Doxorubicin via Acetalated Dextran Scaffold Prevents Glioblastoma Recurrence after Surgical Resection. Graham-Gurysh E; Moore KM; Satterlee AB; Sheets KT; Lin FC; Bachelder EM; Miller CR; Hingtgen SD; Ainslie KM Mol Pharm; 2018 Mar; 15(3):1309-1318. PubMed ID: 29342360 [TBL] [Abstract][Full Text] [Related]
11. Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery. Belhadj Z; Ying M; Cao X; Hu X; Zhan C; Wei X; Gao J; Wang X; Yan Z; Lu W J Control Release; 2017 Jun; 255():132-141. PubMed ID: 28390902 [TBL] [Abstract][Full Text] [Related]
12. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model. Mercurio L; Ajmone-Cat MA; Cecchetti S; Ricci A; Bozzuto G; Molinari A; Manni I; Pollo B; Scala S; Carpinelli G; Minghetti L J Exp Clin Cancer Res; 2016 Mar; 35():55. PubMed ID: 27015814 [TBL] [Abstract][Full Text] [Related]
13. Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells. Mukherjee S; Fried A; Hussaini R; White R; Baidoo J; Yalamanchi S; Banerjee P J Exp Clin Cancer Res; 2018 Jul; 37(1):168. PubMed ID: 30041669 [TBL] [Abstract][Full Text] [Related]
14. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes. Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741 [TBL] [Abstract][Full Text] [Related]
15. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts. Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of Elastin-Like Polypeptides for Tumor Targeted Delivery of Doxorubicin to Glioblastoma. Dragojevic S; Mackey R; Raucher D Molecules; 2019 Sep; 24(18):. PubMed ID: 31489879 [TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-polyglycerol-nanodiamond conjugates disrupt STAT3/IL-6-mediated reciprocal activation loop between glioblastoma cells and astrocytes. Chen Z; Yuan SJ; Li K; Zhang Q; Li TF; An HC; Xu HZ; Yue Y; Han M; Xu YH; Komatsu N; Zhao L; Chen X J Control Release; 2020 Apr; 320():469-483. PubMed ID: 31987922 [TBL] [Abstract][Full Text] [Related]
18. Prolonged survival upon ultrasound-enhanced doxorubicin delivery in two syngenic glioblastoma mouse models. Kovacs Z; Werner B; Rassi A; Sass JO; Martin-Fiori E; Bernasconi M J Control Release; 2014 Aug; 187():74-82. PubMed ID: 24878186 [TBL] [Abstract][Full Text] [Related]
19. LRP1-mediated pH-sensitive polymersomes facilitate combination therapy of glioblastoma in vitro and in vivo. He C; Zhang Z; Ding Y; Xue K; Wang X; Yang R; An Y; Liu D; Hu C; Tang Q J Nanobiotechnology; 2021 Jan; 19(1):29. PubMed ID: 33482822 [TBL] [Abstract][Full Text] [Related]
20. Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival. Catania G; Rodella G; Vanvarenberg K; Préat V; Malfanti A Biomaterials; 2023 Mar; 294():122006. PubMed ID: 36701998 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]